{"id":"NCT02722837","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection","officialTitle":"A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-04","primaryCompletion":"2017-06-26","completion":"2017-09-13","firstPosted":"2016-03-30","resultsPosted":"2018-07-17","lastUpdate":"2018-11-16"},"enrollment":119,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["GS-7977/GS-5816","EpclusaÂ®"]}],"arms":[{"label":"SOF/VEL","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL","deltaMin":99.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":15,"countries":["Russia","Sweden"]},"refs":{"pmids":["30499360"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":119},"commonTop":["Headache","Fatigue","Asthenia"]}}